本公司认为，基于实际业务需求，本次交易实现了本集团首次以票据结算气款。该模式为本公司提供了 低成本资金的同时，优化了本公司的融资结构和财务成本，从而有力支持了本集团的运营与发展需求。 此外，中国石化通过本次交易，持续兑现其助力本集团持续发展的承诺，体现了中国石化作为重要股东 对本公司发展前景的坚定信心与切实担当。 智通财经APP讯，滨海投资(02886)发布公告，本公司全资附属公司天津泰达滨海清洁能源集团有限公司 (天津清洁能源)已经获得中国石化财务有限责任公司天津分公司(中石化财务天津)提供的共计人民币1.5 亿元授信(本次授信)。本次授信将通过中石化财务天津开具的商业承兑汇票，用于结算天津清洁能源向 上游供应商支付的天然气采购款项，并由天津清洁能源承担上游供应商贴现的贴现息(本次交易)。天津 清洁能源与中石化财务天津已经签订《商业汇票承兑合同》，合同有效期截止2025年12月30日。 ...

财通证券股份有限公司 关于 浙江众合科技股份有限公司出售子公司股权被动形成财务 资助暨关联交易的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为浙江 众合科技股份有限公司（以下简称"众合科技"或"公司"）向特定对象发行股 票的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐 业务》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等相关规定，对众合科技出售子公司股权被动形成财务资助暨关联交易事 项进行了审慎核查，具体情况如下： 一、财务资助概述 公司。公司于 2025 年 8 月 14 日召开第九届董事会第十三次会议，审议并通过了 《关于出售子公司部分股权的议案》。公司拟向杭州山屿源环保科技有限公司 （以下简称"山屿源环保"）转让温瑞公司 75.00%的股权。上述交易完成后， 借款利率：按一年期贷款市场报价利率（LPR）上浮 20%，按实际期间计 算利息； 还款约定：于借款到期日一次性归还； 担保措施：山屿源环保提供连带保证责任。 公司于 2025 年 8 月 14 日 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、财务资助情况概述 1、基本情况 南京朗鑫樾置业有限公司（以下简称"朗鑫樾"）系南京公用发展股份有限公司（以下简称"公司"）全资 子公司南京中北盛业房地产开发有限公司（以下简称"中北盛业"）的参股公司，中北盛业持有朗鑫樾 45%股权，南京朗福地产有限公司（以下简称"南京朗福"）持有朗鑫樾30%股权，江苏洛德股权投资基 金管理有限公司（以下简称"洛德基金"）持有朗鑫樾25%股权。朗鑫樾目前主要业务系南京江宁 NO.2017G62项目地块（以下简称"NO.2017G62项目"）的开发建设及销售。 为满足朗鑫樾开发的NO.2017G62项目运营和管理所需的资金需求，经2017年11月13日召开的第九届董 事会第二十四次会议、2017年11月29日召开的2017年第一次临时股东大会审议通过，中北盛业于 NO.2017G62项目开发初始阶段按照同股同权的原则，以股东借款形式向朗鑫樾提供了不超过70,875万 元（年利率8%）的财务资助，期限36个月。具体内容详见公司分别于 ...

证券代码：600807 证券简称：济高发展 公告编号：临2025-044 济南高新发展股份有限公司第十一届董事会第二十四次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司第十一届董事会第二十四次临时会议于2025年8月1日上午10点，在中国（山东）自由贸易试验区济 南片区经十东路7000号汉峪金融商务中心A4-4号楼11层会议室，以现场和通讯结合方式召开，会议通 知和材料于2025年7月28日以电子通讯方式发出。应出席会议董事9名，实际出席会议董事9名，公司监 事列席了会议，符合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。会议召集人、主持人为公司董事长王成东先生。 经投票表决，会议形成如下决议： 具体内容详见同日披露的《关于修订〈公司章程〉并取消监事会及修订部分公司治理制度的公告》； 《济南高新发展股份有限公司章程》详见公司将于2025年第三次临时股东大会召开前披露的股东大会会 议材料。 表决结果：9票同意、0票反对、0票弃权。 二、审议通过《关于审议修订〈股 ...

Core Viewpoint - The company plans to provide financial assistance in the form of a loan not exceeding 6 million yuan to its subsidiary, Shandong Aikewei Biotechnology Co., Ltd., for operational needs, with a loan term of one year and interest rates to be determined based on prevailing bank rates and actual financing costs [1][2][7]. Financial Assistance Details - The financial assistance will not affect the company's normal business operations and funding usage [2][7]. - The loan amount is capped at 6 million yuan, with the interest rate to be negotiated at the time of signing the loan agreement [1][7]. - The financial assistance has been approved by the company's board of directors in a recent meeting [2][7]. Subsidiary Information - Aikewei Biotechnology has a registered capital of 12.31 million yuan and operates in various medical and biotechnology sectors [2]. - As of December 31, 2024, Aikewei's total assets were 672.92 million yuan, with total liabilities of 317.22 million yuan, resulting in a debt-to-asset ratio of 47.14% [3]. - The company reported a net profit loss of 7.48 million yuan for the year 2024 [3]. Related Party Transactions - The shareholder of Aikewei, Jinan High-tech Financial Investment Co., Ltd., is an affiliate of the company, and the financial assistance complies with relevant regulations [2][6]. - The company has not provided any financial assistance to Aikewei in the past 12 months, indicating no overdue financial assistance [7]. Board of Directors' Opinion - The board believes that providing financial assistance to Aikewei is beneficial for its operational needs and aligns with the company's overall strategy, ensuring that risks are manageable and compliant with legal regulations [7].

Group 1 - The board of directors of Shandong Weiming Bio-Pharmaceutical Co., Ltd. held its third meeting of the sixth session on July 25, 2025, with all 11 directors participating [1][2] - The board approved a financial assistance proposal to its controlling subsidiary Sichuan Gukang Pharmaceutical Co., Ltd., allowing a loan of up to 55 million RMB at an interest rate of 1.3% per annum, with a maximum term of one year [1][2] - The financial assistance does not constitute a related party transaction or a major asset restructuring, and it is deemed beneficial for Gukang Pharmaceutical's operational development [2][3] Group 2 - The board approved changes to the management structure of its wholly-owned subsidiary Xiamen Weiming Bio-Pharmaceutical Co., Ltd., appointing Chen Xing as the new legal representative and general manager, and restructuring the governance to a board of directors [1][3] - The changes at Xiamen Weiming do not require shareholder approval and will be finalized upon approval from market supervision authorities [3] - The board also approved an expansion of the business scope for its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd., which will now include various technical services and pharmaceutical production activities [4]

Core Viewpoint - The company is providing financial assistance to its associate company, Jiangxi Huadian Jiujiang Distributed Energy Co., Ltd., in the form of a shareholder loan amounting to 64.827 million RMB, with a term of three years and an interest rate of 3% [2][3][11] Financial Assistance Overview - The financial assistance involves a loan of 64.827 million RMB to Jiangxi Huadian Jiujiang Company, aimed at meeting its operational and developmental funding needs [3] - The loan was approved by the company's board with unanimous support and does not require shareholder meeting approval, thus not constituting a related party transaction [2][3] - Other shareholders of Jiangxi Huadian Jiujiang Company are also providing loans under the same conditions, ensuring no infringement on the company's interests [2][3] Company and Financial Details - Jiangxi Huadian Jiujiang Company was established on March 25, 2011, and focuses on investment in distributed energy projects in Jiujiang City [5][6] - The company has a registered capital of 92.61 million RMB and is primarily engaged in natural gas power generation [5][6] - The financial assistance will be funded from the company's own resources and will not affect its normal business operations [3][11] Risk Control Measures - The company has appointed directors and financial personnel to monitor the operational and loan risks of Jiangxi Huadian Jiujiang Company [4][11] - In case of adverse developments, the company will take timely measures to ensure loan repayment and mitigate financial risks [4][11] Financial Assistance Agreement - The loan agreement specifies that the funds will be used for debt repayment and business operations, with a repayment structure of monthly interest payments and a lump-sum principal repayment at maturity [10] - The company retains the right to demand corrective actions or additional guarantees in case of borrower default [10] Cumulative Financial Assistance - After this loan, the total financial assistance provided by the company amounts to 2.183 billion RMB, representing 14.03% of the latest audited net assets [12] - The financial assistance to external entities amounts to 64.827 million RMB, which is 0.42% of the latest audited net assets, with no overdue amounts reported [12]

Financial Assistance Overview - The company plans to provide financial assistance of RMB 45 million to its subsidiary, Qingdao Borui Zhiyuan Vibration Technology Co., Ltd., to support its business development and operational needs [1][2] - The loan will have a term of 2 years with an annual interest rate of 2.30% [1][4] Reasons and Impact of Financial Assistance - The financial assistance aims to facilitate the subsidiary's business growth and ensure smooth operational cash flow, promoting synergy between the parent and subsidiary companies [1][2] Risk Management Measures - The company holds a 52.07% indirect stake in Qingdao Borui, allowing it to implement effective risk control over its operations and finances [2][4] - The company will enhance daily management of the subsidiary and monitor its financial health to ensure the safety of funds [2][4] Financial Status of the Subsidiary - Qingdao Borui has total assets of RMB 81.844 million and total liabilities of RMB 57.258 million, resulting in a net asset value of RMB 24.586 million [3] - The asset-liability ratio stands at 69.96% [3] Approval Process for Financial Assistance - The financial assistance has been approved by the company's board of directors and does not require further shareholder approval [4] Sponsor's Verification Opinion - The sponsor, Guojin Securities, confirms that the financial assistance complies with relevant laws and regulations and does not harm the interests of the company or its shareholders [4]

Core Viewpoint - The company plans to provide financial assistance to its subsidiaries, Hangzhou Xinshi Semiconductor Co., Ltd. and Chengdu Taitan Testing Technology Co., Ltd., through loans totaling up to 2 billion RMB and 1 billion RMB respectively, to support their business expansion and daily operations [1][2][3] Financial Assistance Overview - The financial assistance will be provided in the form of credit loans without collateral, with a maximum loan amount of 20 million RMB to Hangzhou Xinshi and 10 million RMB to Chengdu Taitan [1][2] - The loan term will not exceed three years from the date of the shareholders' meeting resolution, and the loan amounts can be reused within the term based on actual business needs [1][2][3] Loan Terms - The interest rate will be set at the prevailing Loan Prime Rate (LPR) plus 20 basis points, with interest calculated based on the actual number of days the loan is utilized [2][3] Approval Process - The financial assistance has been approved by the company's board of directors and is pending approval from the shareholders' meeting [2][3] Subsidiary Information - Hangzhou Xinshi Semiconductor Co., Ltd. has a registered capital of 40 million RMB, primarily engaged in chip research, design, and sales, with a 60% ownership by the company [4][6] - Chengdu Taitan Testing Technology Co., Ltd. has a registered capital of 20 million RMB, established for equipment research, production, and sales, with a 60% ownership by the company's wholly-owned subsidiary [7][8] Financial Data of Subsidiaries - As of March 31, 2025, Hangzhou Xinshi reported total assets of 1,828.57 million RMB, a revenue of 1.4 million RMB, and a net loss of 12.29 million RMB [4][6] - Chengdu Taitan reported total assets of 75.41 million RMB, a revenue of 637.25 million RMB, and a net loss of 5.76 million RMB as of March 31, 2025 [8] Risk Management - The company maintains effective control over the use of the financial assistance, ensuring that the funds are utilized appropriately and that risks are manageable [6][9] - The total amount of financial assistance provided after this transaction will be 412.94 million RMB, representing 17.12% of the company's latest audited net assets [10]

Core Viewpoint - The company, Shenzhen Baiwei Storage Technology Co., Ltd., is providing financial assistance to its controlling subsidiaries, aiming to support their business expansion and daily operational funding needs while ensuring that the company's normal operations are not affected [2][3][6]. Financial Assistance Overview - The company plans to lend up to 200 million RMB to its subsidiary Hangzhou Xinshi Semiconductor Co., Ltd. and up to 100 million RMB to Chengdu Taitan Testing Technology Co., Ltd. The loans will be for a maximum period of three years and will be based on actual business needs [2][3]. - The loans are unsecured and will be used for business expansion and daily operational funding [2][5]. Approval Process - The financial assistance has been approved by the company's board of directors and is pending approval from the shareholders' meeting [3][7]. - The financial assistance does not violate any regulations regarding the provision of financial support [3][7]. Subsidiary Information - Hangzhou Xinshi Semiconductor Co., Ltd. has a registered capital of 40 million RMB and is primarily engaged in chip research, design, and sales. The company holds a 60% stake in it [3][4]. - Chengdu Taitan Testing Technology Co., Ltd. has a registered capital of 20 million RMB and focuses on equipment research, production, and sales. The company also holds a 60% stake in this subsidiary [4][5]. Financial Data of Subsidiaries - Hangzhou Xinshi reported total assets of 13.52 million RMB and a net loss of 1.23 million RMB as of March 31, 2025 [4]. - Chengdu Taitan reported total assets of 75.41 million RMB and a net asset of 15.19 million RMB as of March 31, 2025 [4]. Risk Management - The company maintains effective control over its subsidiaries, ensuring that the financial assistance does not pose risks to the company's overall financial health [6][7]. - The total financial assistance provided by the company, including this round, will amount to 412.94 million RMB, which is 17.12% of the company's latest audited net assets [6][7]. Board Opinion - The board believes that providing financial assistance to the subsidiaries aligns with the company's overall interests and will enhance the efficiency of fund utilization while minimizing financing costs [6][7].